Genenta Science S.p.A. filings document a foreign private issuer reporting on Form 6-K, with disclosures incorporated by reference into its Form F-3 registration statement when specified. The record covers material events, shareholder voting matters, capital-structure updates, operating and financial results, and clinical or regulatory disclosures for its biotechnology platform and Temferon program.
The filings also document governance and corporate-structure actions, including the approved expansion of the company’s corporate purpose to sectors covered by Italian Golden Power legislation, board changes, listing-compliance notices, material agreements, and decisions to streamline subsidiaries and finance-function arrangements as Genenta pursues an Italy- and Europe-focused industrial aggregator strategy.
Genenta Science S.p.A. has received a Nasdaq notice that its American Depositary Shares no longer meet the exchange’s minimum bid price requirement of $1 per share under Nasdaq Listing Rule 5550(a)(2). The closing bid stayed below this level from February 26 to April 9, 2026.
The company retains its listing for now and has 180 days, until October 7, 2026, to regain compliance. If it qualifies under other Nasdaq Capital Market standards, it may receive an additional 180-day period, potentially using a reverse stock split. Management is evaluating options but cannot assure successful or timely compliance.
Genenta Science S.p.A. reported that its CMO & Head of Development, Francesco Galimi, received a grant of stock options covering 20,000 American Depositary Shares. The options have an exercise price of $0.63 per share and expire on December 31, 2035.
The options vest in equal monthly installments over one year beginning March 30, 2026. Following this grant, Galimi holds stock options for 20,000 ADS directly, reflecting a compensation-related award rather than an open-market transaction.
Genenta Science S.p.A. director Giacomoantonio Paracchi reported a compensation-related grant of stock options. On March 30, 2026, he was awarded options covering 20,000 American Depositary Shares at an exercise price of $0.63 per share, expiring on December 31, 2035.
The options vest in equal monthly installments over one year beginning March 30, 2026, aligning the award with ongoing service. Following this grant, Paracchi holds 20,000 stock options directly.
Genenta Science S.p.A. director Sharei Armon received a grant of stock options for 20,000 American Depositary Shares. The options have an exercise price of $0.63 per share and expire on December 31, 2035. They vest in equal monthly installments over one year beginning March 30, 2026.
Genenta Science S.p.A. director Mutti Miguel Maria received a grant of stock options covering 20,000 American Depositary Shares. The options were granted at no cost, with an exercise price of $0.63 per share and an expiration date of December 31, 2035.
The options vest in equal monthly installments over one year beginning March 30, 2026, aligning the director’s compensation with longer-term company performance. Following this grant, the director holds 20,000 stock options directly, with no open-market share purchases or sales reported in this filing.
Genenta Science S.p.A. reported that Chief Financial Officer Richard B. Slansky received a grant of stock options covering 80,000 American Depositary Shares. The options have an exercise price of $0.63 per share and expire on December 31, 2035.
The award was granted at no cost and is a compensation-related acquisition, not an open-market purchase. According to the footnote, the options vest in equal monthly installments over three years beginning March 30, 2026, and all 80,000 options were reported as held directly following the transaction.
Genenta Science S.p.A. files its Form 20-F annual report for the year ended December 31, 2025, detailing its clinical-stage gene therapy business and strategic shift toward industrial consolidation in national security–related sectors.
The company reports 23,432,183 ordinary shares outstanding as of December 31, 2025 and cash, cash equivalents and marketable securities of about €28.1 million. It remains loss-making, with 2025 net loss of roughly €6.5 million and an accumulated deficit of about €62.6 million.
Genenta highlights substantial financing flexibility, including a $100.0 million shelf registration with approximately $86.0 million remaining and an at-the-market facility with about $26.4 million of capacity left. Extensive risk disclosures emphasize ongoing funding needs, clinical and regulatory uncertainties for Temferon, and execution risks in its planned transformation into a “next-generation strategic industrial consolidator.”
Genenta Science is pursuing a binding offer to acquire up to 51% of Sòphia High Tech, an Italian aerospace and defense manufacturer, by funding EUR 6.0 million through two reserved capital increases and payments to the founders, with the second tranche tied to EBITDA milestones.
The offer includes an initial 30% stake, a performance-based earnout and a 90-day exclusivity period, and is subject to confirmatory due diligence, required government approvals and definitive documentation. Genenta is evolving into Saentra Forge, a strategic consolidator in biotech, defense, aerospace and Italian national-security sectors, with Sòphia HT described as already profitable and projecting EBITDA growth.
Genenta Science S.p.A. director Giacomoantonio Paracchi has filed an initial Form 3 ownership report indicating that he does not currently own any ordinary shares, American Depositary Shares, or derivative securities of the company. Each American Depositary Share represents one ordinary share with no par value.
Genenta Science S.p.A. has cancelled its previously scheduled Extraordinary Shareholders’ Meeting of March 25–26, 2026, which was convened to approve a change of the company’s name to Saentra Forge S.p.A. and a related Nasdaq ticker change.
The board decided to revoke the meeting call after concluding that the Genenta name still carries strong recognition, value, and market presence built over more than a decade. The company notes that the already approved extension of its corporate purpose, linked to Italy’s Golden Power legislation, remains in an early development phase, and the Saentra Forge branding requires further positioning before any future rebrand.